Dr. Casey L. O'Connell, MD

Dr. O'Connell practices at USC Norris Cancer Hospital in Los Angeles, California.

Dr. O'Connell's NPI, 1104039197, was assigned on May 7, 2007. Dr. O'Connell graduated from George Washington University School of Medicine and Health Sciences in 2001. Dr. O'Connell holds California license A80627.

Dr. O'Connell's primary practice is USC Norris Cancer Hospital, at 1441 Eastlake Ave, Los Angeles, CA.

Dr. O'Connell's primary practice is USC Norris Cancer Hospital in Los Angeles, California. Dr. O'Connell is also affiliated with Los Angeles General Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. O'Connell to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Connell practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. O'Connell's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. O'Connell is board certified in hematology by the American Board of Internal Medicine. Dr. O'Connell is licensed in California.

Dmand AI lists chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), immune deficiency disease, lung cancer, lymphoma and neutropenia among the conditions Dr. O'Connell treats.

CMS data shows 633 Medicare services from Dr. O'Connell across 9 procedure codes in 2024, for 316 Medicare patients. Medicare paid $42,481 for them.

CMS counts 316 Medicare patients who saw Dr. O'Connell in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. O'Connell's median patient age at 64, with 47% women.

In 2024, Dr. O'Connell wrote 219 Medicare Part D claims for 60 patients. 58% of them were for generic drugs. CMS names the drug for 74 of them, across 4 drugs with 11 or more claims each, at $164,155 in total drug cost. In 2023, CMS named 96 claims across 6 drugs.

Dr. O'Connell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Connell as offering telehealth.

Dmand AI links 58 papers to Dr. O'Connell, published from 2011 to 2025. 2016 was the busiest year, with 7. The most frequent topics are Venous Thromboembolism, Leukemia, Myeloid, Acute and Anticoagulants. Dr. O'Connell has published most often in Blood. Dr. O'Connell's most frequent co-authors are Gail J. Roboz, MD, Howard A. Liebman, MD and Ruben Anthony Mesa, MD.

Dmand AI links Dr. O'Connell to 14 clinical trials, 5 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases and Leukemia, Myeloid, Acute. Astex Pharmaceuticals, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. O'Connell that name 1 trial.

CMS Open Payments shows 69 general payments to Dr. O'Connell from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. Otsuka Pharmaceutical Development & Commercialization, Inc. paid the most, $6,089. It also lists 1 research payment totaling $50,430 in 2019, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. O'Connell.

Dr. O'Connell graduated from George Washington University School of Medicine and Health Sciences in 2001.

Dr. O'Connell is in network with 15 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.